The new sequencing panel can study known clinically-relevant gene fusions, 3’/5’ imbalance markers, exon skipping events, and mRNA expression levels in non-small cell lung cancer (NSCLC) samples.
QuantideX RNA lung cancer kit, which is an end-to-end NGS-in-a-Box product solution, has been developed for use with low-quality and quantity samples such as FFPE and fine-needle aspirations.
The sensitive assay can detect fusions and splice variants at 5% and 1% cell fractions.
With its integrated workflow, the kit can deliver sequencing-ready libraries in around half the time of compared to competitor methods and and incorporates push-button analytics that standardize results.
According to the firm, the assay is for research use only and cannot be used in diagnostic procedures.
The firm’s Sample-Aware bioinformatics software solution is said to minimize the subjective results commonly associated with less integrated product offerings currently on market
Asuragen president and CEO Dr Matthew McManus said: “With the release of this new RNA-Seq assay, Asuragen is providing the most comprehensive and sensitive research tool for examining >100 clinically-relevant NSCLC gene rearrangements across 11 different fusion partners.”
“In providing an integrated and comprehensive workflow solution, Asuragen’s NGS assays reduce the barrier-to-entry for laboratories considering targeted NGS oncology assays while also providing new options for laboratories already familiar with NGS technology.”
Asuragen also produces Quantidex pan cancer kit, which is a workflow solution for targeted next-generation sequencing (NGS). It incorporates reagents, controls and bioinformatics suite for the sequencing of 21 genes relevant to a diverse set of human cancers.
Quantidex pan cancer kit was developed to examine difficult sample types such as formalin-fixed paraffin embedded (FFPE) and fine-needle aspiration (FNA) tissues.
